文献速递青光眼

多基因风险评分影响青光眼终身风险与预后

Polygenic Risk Impacts Lifetime Risk and Prognosis of Glaucoma.
PubMed 文献 · Ophthalmology · 2026-06-11

最佳PRS对青光眼的风险比为3.32(95%CI 3.21-3.43),终身风险从<第1百分位的2.5%升至≥第99百分位的45.3%,且高PRS十分位者20年内需更多药物升级、激光和手术。

要点

  • 最佳PRS的HR为3.32(95%CI 3.21-3.43),≥90th vs 20th-80th百分位。
  • 终身风险从<第1百分位的2.5%升至≥第99百分位的45.3%。
  • 最高PRS十分位者20年药物升级、激光和手术累积发生率更高。

核心结论

  • 青光眼PRS可有效分层终身风险,中年时已显现明显分层,且比家族史更精确。
  • PRS能分层预后指标,包括药物升级和手术干预,支持PRS指导筛查和管理。

主要发现

  • 最佳PRS的HR为3.32(95%CI 3.21-3.43),比较≥90th与20th-80th百分位。
  • 终身风险从<第1百分位的2.5%(95%CI 1.7%-3.3%)升至第95-99百分位的31.9%(95%CI 30.5%-33.3%)和≥第99百分位的45.3%(95%CI 42.3%-48.1%)。
  • 家族史与PRS独立贡献风险,校正家族史后PRS效应量仅降低4.2%。
  • 20年随访中,最高PRS十分位者药物升级累积发生率60.6% vs 最低十分位38.4%,激光39.8% vs 22.9%,手术15.8% vs 9.5%。

关键数值与推荐

  • 最佳PRS的HR为3.32(95%CI 3.21-3.43),≥90th vs 20th-80th百分位。
  • 终身风险:<第1百分位2.5%(95%CI 1.7%-3.3%),第95-99百分位31.9%(95%CI 30.5%-33.3%),≥第99百分位45.3%(95%CI 42.3%-48.1%)。
  • 20年累积发生率:药物升级60.6% vs 38.4%,激光39.8% vs 22.9%,手术15.8% vs 9.5%(最高vs最低PRS十分位)。

临床怎么用

  • 可利用PRS对个体进行青光眼终身风险分层,中年时即可识别高风险者。
  • 高PRS十分位者可能需要更密切监测和更积极治疗,因药物升级和手术风险更高。
  • PRS可补充家族史信息,用于指导筛查和管理策略。

局限性

  • 研究为生物银行队列,需前瞻性研究评估临床实施和成本效益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the clinical usefulness of a glaucoma polygenic risk score (PRS) for glaucoma by benchmarking published glaucoma PRSs and by assessing how the best-performing PRS performs for assessing glaucoma risk, age at onset, and glaucoma prognosis. DESIGN: Cohort study. PARTICIPANTS: Four hundred two thousand seven hundred thirty-nine individuals in FinnGen, with 21 609 individuals who received a glaucoma diagnosis after 40 years of age. MAIN OUTCOME MEASURES: Lifetime risk of glaucoma, the need and escalation of intraocular pressure-lowering medication, need for laser therapies, and need for incisional surgery. METHODS: Fourteen published glaucoma PRSs from the Polygenic Score Catalog were benchmarked comprehensively using Cox proportional hazards models. The best-performing PRS was selected to evaluate further the lifetime risk of glaucoma by 85 years of age using Kaplan-Meier survival analyses, both alone and alongside family history information. In addition, the impact of PRS on prognostic outcomes was assessed over a 20-year follow-up period. RESULTS: The PRS with the best performance had a hazard ratio (HR) of 3.32 (95% confidence interval [CI], 3.21-3.43) for glaucoma (≥90th PRS percentile vs. 20th-80th percentile). Lifetime risk of glaucoma increased considerably across PRS categories from 2.5% (95% CI, 1.7%-3.3%) among individuals in the less than first percentile, to 31.9% (95% CI, 30.5%-33.3%) in the 95th to 99th percentiles, and to 45.3% (95% CI, 42.3%-48.1%) in the 99th percentile or more. Family history and PRS contributed independently to glaucoma risk, with the PRS effect size decreasing only by 4.2% when adjusting the PRS effect for family history. Those in the highest PRS decile required more intensive glaucoma care, with higher cumulative incidences of medication escalation (60.6% vs. 38.4%), laser therapies (39.8% vs. 22.9%), and incisional surgeries (15.8% vs. 9.5%) compared with the lowest PRS decile over a 20-year follow-up. CONCLUSIONS: In this large biobank study, a glaucoma PRS effectively stratified individuals according to their lifetime risk of glaucoma, with substantial stratification evident already by midlife. The PRS provided a more precise risk assessment than family history alone, and it was effective in stratifying individuals based on several prognostic measures, including medical treatment escalation and surgical interventions. These findings support the potential usefulness of PRS-guided screening and management strategies in glaucoma, with future prospective studies warranted to evaluate the clinical implementation and cost-effectiveness. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Tusa ES, Tamlander M, Ripatti S, et al. Polygenic Risk Impacts Lifetime Risk and Prognosis of Glaucoma. Ophthalmology. 2026. PMID: 42276423. doi:10.1016/j.ophtha.2026.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。